US approves India's Ranbaxy to make generic Lipitor

Indian pharmaceutical giant Ranbaxy won US regulatory approval to make the first generic version of cholesterol lowering drug Lipitor, a Pfizer product whose patent expired Wednesday.

Ranbaxy had faced delays in gaining US approval due to problems with quality control at some of their Indian factories.

The FDA on Wednesday "approved the first generic version of the Lipitor (atorvastatin calcium tablets)," an agency statement said.

"Ranbaxy Laboratories Ltd. has gained approval to make generic atorvastatin calcium tablets in 10 milligram, 20 mg, 40 mg, and 80 mg strengths. The drug will be manufactured by Ohm Laboratories in New Brunswick, New Jersey."

Lipitor was the best-selling drug of all-time, and earned Pfizer 100 billion dollars since coming on the market in 1997.

In the United States, anti-cholesterol drugs account for 255 million prescriptions a year, and about nine million people are taking Lipitor.

US-based Watson Pharmaceuticals earlier announced its launch of a generic version of Lipitor, atorvastatin calcium, under an exclusive supply and distribution agreement with Pfizer, whereby Pfizer manufactures the drug and Watson sells it, sharing net sales with Pfizer until 2016.

add to favorites email to friend print save as pdf

Related Stories

Pfizer's blockbuster drug Lipitor goes generic

Nov 30, 2011

Pfizer's patent on the best-selling drug of all-time, the cholesterol-lowering medication Lipitor, expired on Wednesday, opening the path to generic competitors for America's most popular medication.

Pfizer drug found with serious side effect

Nov 01, 2006

U.S. pharmaceutical company Pfizer Inc. says clinical trials of its heart medication torcetrapib suggest the drug has a potentially serious side effect.

Pfizer gets EU approval for kids' cholesterol drug

Jul 06, 2010

(AP) -- The European Union has approved a new chewable form of cholesterol blockbuster Lipitor for children 10 and up with high levels of bad cholesterol and triglycerides, a type of blood fat, Pfizer said Tuesday.

Pfizer maneuvers to protect Lipitor from generics

Nov 29, 2011

(AP) -- Lipitor is so valuable that its maker, Pfizer Inc., is practically paying people to keep taking the blockbuster cholesterol medicine after generic competition hits the U.S. market this week.

Recommended for you

Discount generic drug programs grow over time

22 hours ago

Generic discount drug programs (GDDPs, which charge nominal fees to fill prescriptions) have grown over time and their initial lower use by racial/ethnic minorities has evaporated, writes author Song Hee Hong, Ph.D., of the ...

Seniors successfully withdraw from meds

Sep 19, 2014

Elderly people have proved receptive to being de-prescribed medications, as part of a trial aimed at assessing the feasibility of withdrawal of medications among older people.

User comments